

# Humira<sup>®</sup> Biosimilars Schedule

The world's best-selling biologic will have at least eight competing biosimilars in the U.S. market across 2023.

Since these products will be adjudicated under the pharmacy benefit (vs. the medical benefit for many biologics), they bring optimism for cost savings but also a host of new plan design considerations.

RxSS has been tracking biosimilar development for years. Our clinical engine is already equipped for their market entry and **can align with any plan design or specialty strategy for lowest net cost.**

## 3 Things to Know

- 1 Amjevita<sup>™</sup> will likely enjoy market exclusivity for the first six months of 2023.

**Why it Matters:** As the first and only Humira biosimilar available for nearly half the year, and with no competition beyond the reference product, list pricing may peak during the first 180 days.

- 2 Cyltezo<sup>®</sup> is the only biosimilar that's designated as interchangeable with Humira.

**Why it Matters:** It can be substituted for Humira at the pharmacy without additional approvals from the prescribing physician, state law permitting. There is no additional risk or reduced effectiveness if a patient switches back and forth between an interchangeable biosimilar and a reference product.

- 3 PBMs typically update formularies quarterly.

**Why it Matters:** Given that five biosimilars are poised to enter the market mid-year, watch closely for formulary updates that include biosimilar additions in July and October, which may have significant impact on strategy.

## Approved Indications

- Rheumatoid arthritis
- Polyarticular juvenile idiopathic arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Hidradenitis suppurativa
- Crohn's disease
- Ulcerative colitis
- Plaque psoriasis
- Panuveitis



## Key Drop Dates to Watch for in 2023

**January 31**

Amjevita<sup>™</sup> (Amgen)

**June 30**

Hadlima<sup>™</sup> (Merck)

**July 1**

Abrilada (Pfizer)  
Yusimry<sup>™</sup> (Coherus)  
Cyltezo<sup>®</sup> (Boehringer Ingelheim)  
Idacio<sup>®</sup> (Fresenius Kabi)

**July 31**

Hulio<sup>™</sup> (Mylan)

**September 30**

Hyrimoz<sup>™</sup> (Sandoz)



## WANT MORE?

If you have questions or need to make sense of biosimilars, let's talk! Email us at [sales@rxss.com](mailto:sales@rxss.com).